Quarterly ResultMay 15, 2026, 04:43 PM
Scienture Holdings Q1 Net Loss $3.4M; Revenue Jumps to $56K
AI Summary
Scienture Holdings, Inc. reported a net loss of $3.40 million for the first quarter of 2026, an increase from $3.06 million in the prior year, despite a significant rise in revenues to $56,325 from $10,258. The company's cash and cash equivalents decreased to $3.54 million from $6.66 million at year-end 2025. Management acknowledges a "going concern" risk due to an accumulated deficit of $83.95 million but expects commercialization of ARBLI (SCN-102) and planned financing to fund operations for the next 12 months. The company completed strategic divestments in 2025 to focus on branded and specialty pharma.
Key Highlights
- Net loss increased to $3.40 million in Q1 2026 from $3.06 million in Q1 2025.
- Revenues surged to $56,325 in Q1 2026, up from $10,258 in Q1 2025.
- Basic net loss per common share improved to $(0.08) from $(0.33) year-over-year.
- Cash and cash equivalents decreased to $3.54 million as of March 31, 2026, from $6.66 million at December 31, 2025.
- Accumulated deficit reached $83.95 million as of March 31, 2026.
- Net cash used in operating activities was $2.92 million in Q1 2026.
- Company completed divestments of Bonum Health, Softell, and IPS in 2025.
- Management believes existing cash and ARBLI (SCN-102) commercialization will fund operations.
Price Impact
More from SCNX